Navigation Links
Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007
Date:9/26/2007

Presentations to illustrate wide applicability of JuvImmune and JuvaVax

product platforms

PLEASANTON, Calif., Sept. 26 /PRNewswire/ -- Juvaris BioTherapeutics, Inc. announced today six scientific presentations at the upcoming IDSA meeting on October 6, 2007. The data will cover the consistency in multiple species of JuvImmune immunostimulant and JuvaVax products being developed for HIV, influenza, hepatitis and HSV-2.

"We are pleased that the company and its collaborators are presenting a number of high quality papers at the IDSA meeting in San Diego," said Martin D. Cleary, Co-founder, Chairman and CEO of Juvaris. "We believe these presentations demonstrate the wide applicability of the Juvaris JuvImmune and JuvaVax vaccine platforms for prophylaxis and treatment of infectious disease."

About Juvaris

Juvaris BioTherapeutics was created in 2003 to develop an immunotherapeutic product platform for the treatment of infectious diseases and cancers using lipid-DNA complexes. Cationic lipids are formulated with non-coding DNA (plasmid) to create the JuvImmune Immunostimulant, a lipid-DNA complex, which as a single product will have utility in multiple infectious disease and cancer applications. The JuvImmune product has been shown to be at least 50-times more potent at triggering innate immune activation and interferon release than current immune stimulants.

When combined with disease-specific antigens, the technology creates JuvaVax vaccines capable of activating substantial antibody- and cell-mediated immune responses, particularly induction of cytotoxic T lymphocytes (CTL). Immunological responses elicited by the lipid-DNA complexes have been successfully demonstrated in both prophylactic and therapeutic settings in a variety of mammals including rodents, rabbits, cats, dogs and non-human primates. This platform provides the opportunity to develop many disease-specific immunotherapy products, for which
'/>"/>

SOURCE Juvaris BioTherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... and difficult to manufacture proteins including biosimilar therapeutics, ... results for the second quarter ended June 30, ... our initial public offering, we have the capital ... derived from our proprietary protein expression platform," stated ...
(Date:8/29/2014)... According to a new market report published ... market was valued at USD 3,754.6 million in 2012 and ... 2019at a CAGR of 5.9% from 2013 to 2019. , ... is afflicted by bone and joint disorders, and this number ... has and will continue to increase the demand for orthobiologics. ...
(Date:8/29/2014)... 2014 Local veterinarian, Dr. Keith Clement, ... seeking candidates to participate in an investigational study of ... ultimate goal of this study is to determine if ... or two arthritically affected joints can help reduce pain ... for the current investigational study must be older than ...
(Date:8/29/2014)... 29, 2014 A major challenge before ... start-up dense realm of Boston-Cambridge, is gaining visibility that ... James Sherley, the Director of Boston’s Adult Stem Cell ... and national visibility of his company an important priority ... In addition to a social media marketing campaign ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4
... LLC, a clinical-stage drug development company commercializing first-in-class ... completion of a $2.9 million private placement. ... and clinical programs for its lead drug compound, ... David G. Kalergis, Chief Executive Officer of Diffusion ...
... 6 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ("China ... CSKI ), a leading,fully integrated pharmaceutical company ... ("PRC"), today announced that the Company,s,Chief Financial Officer, ... meetings at the upcoming Roth 21st Annual OC ...
... Tigris Pharmaceuticals, Inc., a privately held drug development ... Investigational New Drug (IND) application with the U.S. ... novel anticancer compound. GGTI-2418 is a synthetic ... appears to induce apoptosis by downregulating several pivotal ...
Cached Biology Technology:Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida 2Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida 3China Sky One Medical, Inc. CFO to Present at Roth Conference 2China Sky One Medical, Inc. CFO to Present at Roth Conference 3Tigris Pharmaceuticals Files IND Application for GGTI-2418 2Tigris Pharmaceuticals Files IND Application for GGTI-2418 3
(Date:8/29/2014)... of Texas Medical Branch at Galveston has gone on record ... protect monkeys against a lethal dose of Ebola virus up ... disease is severe. , Thomas Geisbert, professor of microbiology and ... advances in Ebola treatment research. The filoviruses known as Ebola ... pathogens, with fatality rates of up to 90 percent. ...
(Date:8/29/2014)... researchers explored the type and number of connections in ... plays on robustness in a study published in ... found that the assortativity signature contributes to a network,s ... that varying the out-out assortativity of TFN models has ... the other three types of assortativity," said Dov A. ...
(Date:8/29/2014)... This news release is available in German . ... of chemical signals between organisms is considered the oldest ... social interactions between conspecifics, for example, the sexual attraction ... trigger social responses and to coordinate reproductive behavior in ... at the University of the Algarve in Faro, Portugal, ...
Breaking Biology News(10 mins):Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Assortativity signatures of transcription factor networks contribute to robustness 2Ready for mating at the right time 2Ready for mating at the right time 3
... the observation that a large group of seemingly unconnected ... Now a multi-national research team led by the Melbourne ... has joined the proverbial dots and identified a potential ... paper published today in the prestigious Nature Medicine journal. ...
... (IAA), commonly referred to as auxin, plays a major ... development by affecting the expression of numerous genes that ... in specific plant tissues at specific stages during the ... floral organs to develop in the correct patterns and ...
... them the Dirt Doctors, or Sultans of Soil, they're just ... has a paper in this week's Science Magazine with a ... in the highly complex world beneath our feet. , "Computational ... Soil," by Jason Gans, Murray Wolinsky and John Dunbar, of ...
Cached Biology News:Scientists find microRNAs regulate plant development 2Scientists find microRNAs regulate plant development 3Scientists find microRNAs regulate plant development 4Comparison of Cocaine, Methamphetamine ‘Highs?Finds Differences 2
Schneider's Drosophila - Insect medium...
... and easy operation of a wide range ... The software is fully secure and compliant ... 11 regulations, and compatible with user-created macros ... enables use in high-level research and development ...
... is a proteohormone with a molecular weight of 16 ... ob gene and produced by adipocytes [1,2]. Leptin ... regulation of body weight [1-3]. In the human, ... men and women [4]. A relationship between serum ...
... Components in this kit are prepared ... technology. Biochains Mitochondria Isolation Kit is ... in a fast and easy way. One ... performing 100 isolations (enriching mitochondria from 10 ...
Biology Products: